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The incidence of penicillin resistance amongst Streptococcus pneumoniae is increasing on a world-wide basis. Penicillin- 
resistant strains of viridans streptococci have also been reported, associated with serious clinical infections, particularly 
in neutropenic patients. Although there are fewer data on the epidemiology of viridans streptococci, it is known that 
penicillin resistance determinants can be transferred between these organisms and S. pneumoniae. Paradoxically, the 
increased incidence of multiresistant pneumococci has led to a re-evaluation of p-lactam antibiotics for the treatment of 
streptococcal infections. 
Cefotaxime, ceftriaxone, cefpirome, cefepime, imipenem, meropenem and amoxicillin remain the most potent 
p-lactam antibiotics, with at least 95% of penicillin-resistant strains of S. pneumoniae being inhibited by 2 mg/L and 95% 
of penicillin-resistant viridans streptococci by 8 mg/L. Cefpirome is two-fold more active than cefotaxime, ceftriaxone or 
cefepime and, like penicillin and cefotaxime, is bactericidal at 2x and 4x the MIC value against penicillin-resistant strains 
of S. pneumoniae and viridans streptococci. Synergistic interactions have been demonstrated between penicillin or 
cefpirome and vancomycin, fosfomycin or gentamicin. 
Studies have shown that the clinical outcome of pneumonia is not related to in vitro MIC data below 4 mg/L, since 
infections caused by penicillin-resistant pneumococci responded as well to p-lactam therapy as those caused by penicillin- 
susceptible strains. This is most likely to be due to high antibiotic concentrations achieved at the site of infection following 
intravenous dosage, which are sufficient to cover strains with reduced susceptibility. Any degree of penicillin resistance 
rules out the use of penicillin for pneumococcal meningitis, necessitating the use of extended-spectrum cephalosporins, 
such as cefotaxirne or ceftriaxone. An alternative could be the use of the fourth-generation cephalosporins or the 
carbapenems. Overall, when predicting the clinical outcome of infections caused by penicillin-resistant streptococci, it is 
important to consider the relationship between a number of factors, namely, the specific susceptibility of the infecting 
strain to the chosen agent, the type of infection (i.e. pneumonia, bacteremia or meningitis) and the relevant antibiotic 
concentrations achieved over time at the site of infection (i.e. those in serum or cerebrospinal fluid). 
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I NTRO DU CTlO N 
Streptococcus pueumoniae is a major bacterial pathogen 
responsible for respiratory tract infections, including 
community-acquired and nosocomial pneumonia. It 
is also the most important bacterial pathogen causing 
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meningitis and acute otitis media, and the increasing 
incidence of antibiotic-resistant strains has made the 
treatment of these infections a difficult and 
controversial topic. The first penicillin-resistant strain 
of S.  pneumoniae was reported in 1967 [l] and, since 
then, the incidence of penicillin resistance has 
increased dramatically world-wide. A number of 
countries, including Spain [2], Hungary [3] and South 
Africa [4], have a particularly high prevalence of 
penicillin-resistant pneumococci (44-59%), as well as 
France (40-45%), which may be related to patterns of 
antibiotic usage in these areas [3,5,6]. There is also 
some evidence that penicillin-resistant clones of 
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S .  pneumoniae belonging to serotype 6B and 23F have 
been exported from these countries to others, for 
example, from Spain to Iceland [7], France [8], South 
Africa [9] and the United States [lo], and these have 
been tracked by molecular analysis of the strains. 
Other serotypes, such as 19B, are prevalent in 
countries such as Japan [11,12]. 
Although viridans-group streptococci, comprising 
the species S. rnitis, S. sanguis, S .  mg inosus  and 
S .  s a l i v a r i m ,  have long been known to cause 
endocarditis, they were previously regarded as minor 
pathogens in other clinical settings. They have now 
become a prominent cause of bacteremia in neutropenic 
patients [ 13,141. Penicillin-resistant strains of viridans 
streptococci have been known since 19612 [15-171. 
Many penicillin-resistant strains of streptococci, 
particularly the highly penicillin-resistant strains, are also 
resistant to other antibiotics [5,6,18] such as macrolides, 
tetracyclines, co-trimoxazole and chloramphenicol. 
Since agents such as the currently available quinolones 
are generally not highly potent against streptococci, 
the therapeutic options for serious infections caused by 
these organisms are limited. 
The p-hemolytic streptococci (groups A, B, C and 
G) cause 3.3%) of bloodstream infections [19]. The 
virulence of this group of organisms, and consequent 
high morbidity or mortality in even previously healthy 
subjects, gives P-hemolytic streptococci clinical 
significance [20]. During the last few years, there has 
been an increase in the number of reports of serious 
infections caused by group A streptococci including 
bacteremia, toxic shock and necrotising fasciitis. These 
streptococci have become increasingly important 
because of modified virulence of S. pyogenes strains 
[ 191. Strains of S. pyogenes are increasingly resistant to 
the macrolides [20] and there is a fear that they may also 
develop resistance to penicillin and other p-lactam 
antibiotics. 
EPI DEM 1010 GY 
The epidemiology of pneumococcal resistance has 
changed over the last few years and has spread to 
countries with previously low levels of resistance [21]. 
High level penicillin resistance for S. pneurnoniae is 
defined as a minimum inhibitory concentration 
(MIC) 2 2 mg/L, intermediate penicillin resistance as 
an MIC of 0.12-1 mg/L and susceptibility as an MIC 
of I 0.06 mg/L. Figure 1 shows the current situation 
regarding resistance to penicillin amongst S .  pneurnoniae 
strains isolated from approximately 200 centers, mainly 
between 1993 and 1996 [Klugman and Baquero, review 
of published and unpublished data]. Penicillin resistance 
is defined here and in Figure 1, as an MIC value 
greater than 0.12 mg/L and, therefore, includes both 
intermediate and high-level penicillin-resistant strains. 
Resistant pneumococci were commonly isolated 
in South Africa, Spain, Papua New Guinea and Eastern 
Europe in the early 1980s. However, other countries, 
such as France, Argentina, Uruguay, Mexico, Israel, 
Saudi Arabia, Nigeria, Kenya and Japan are currently 
reporting incidences of > 40%. Recent data available 
from Korea shows a very high incidence of > 60%, 
although many of these strains are nosocomially- 
acquired. Ninety-five percent of nosocomially-acquired 
pneumococcal bacteremias at  the Baragwanath 
Hospital, Soweto are penicillin-resistant [22]. Rates of 
20-30% are reported in countries such as Turkey, 
Venezuela, Brazil and Chile and in most states in the 
USA [23]. In contrast, low levels of resistance are 
reported in most northern European countries, 
Greece and Italy. Rates of 5, 27 and 10% have been 
reported from Moscow, Smolensk and St. Petersburg 
respectively, but more data are needed from Russia. 
The maximum levels of resistance are currently a 
penicillin MIC of 8 mg/L, reported for strains of 
S. pneumoniae in France [6] and Spain, and 16 mg/L 
in Hungary [24]. Penicillin-resistant S. pneurnoniae are 
isolated at a greater frequency from hospitalized children, 
children in day-care centers and those previously 
exposed to antibiotics, particularly those with acute otitis 
medla. These factors may explain local discrepancies with 
very high incidences of penicillili-resistant strains [6]. 
Since 1983, there have been several reports 
disclosing high level penicilli t i  resistance anlong 
viridans streptococci isolated from clinically significant 
infections [15-171. For viridans streptococci, high 
level penicillin resistance is defined as an MIC of 
2 4 mg/L, intermediate resistance as 0.25-2 mg/L and 
susceptiblility as < 0.25 mg/L 1251. I n  recent studies in 
the USA, only 44-49% of viridans streptococci isolated 
from blood were susceptible to penicillin [19,26,27]. 
The US data are similar to South African figures of 
42-67% susceptibility [17], whereas data from 
Switzerland (1988-1991) indicate that 15% of strains 
are penicillin-resistant [28]. Among the South African 
strains, 8% had penicillin MIC values 2 4 nig/L, as had 
13.4% of strains from the USA [26]. Strains with similar 
levels of resistance have been reported in Europe [28]. 
MOLECULAR BASIS OF RESISTANCE 
The target sites for p-lactani antibiotics are the 
penicillin-binding proteins (PBPs). Resistance is 
mediated by molecular changes which occur within 
the PBPs [16,29,30] (Table l ) ,  which confer reduced 
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Table 1 Penicillin-binding proteins (PBPs) modified to give different penicillin and cephalosponn rcsistaiice phenotypes in 
streptococci 
Phenotype 
Penicillin 
susceptibility 
Cephalosponn 
Susceptibility 
PHPF modified 
Sensitive 
Very low level resistance 
Intermediate 
Resistant 
Intcrniediate 
Resistant 
Sensitive 
Sensitive 
Sensitive 
Sensitive 
Resistant 
Resistant 
N = Normal PBP. 
P = PBP mutated to give reduced susceptibility to penicillin 
C = PBP mutated to give cephalosporin resistance. 
susceptibility to all p-lactam antibiotics to a greater or 
lesser extent [31]. Wild-type strains with a very low or 
intermediate level of resistance to penicillin possess 
mutations in PBP 2x, and when a modification in 
PBP 2b is added, a change from intermediate 
resistance to high-level penicillin resistance occurs 
[32]. Sequential mutations in the gene encoding a 
penicillin-susceptible PBP 2b can also occur, each of 
which further increases the level of resistance to 
penicillin. Acquisition of blocks of DNA to make up 
a mosaic pattern of DNA, encoding resistant parts of 
the protein, is the hallmark of the chLanges in the 
PBP genes. The ‘resistant’ blocks are acquired by 
homologous recombination in these naturally 
transformable organisms [33]. 
A specific alteration at position 550 of PBP 2x, in 
the presence of altered PBP la,  results in high-level 
cephalosporin resistance, but with an intermediate level 
of resistance to penicillins [34]. Multiresistance to both 
penicillins and cephalosporins, which occurs frequently, 
caused by double mutations in PBPs l a  and 2x, 
decreasing the susceptibility to both classes, as well as 
mutations in PBP 2b, giving high-level penicillin- 
resistance. There is evidence that the alcered PBPs in 
viridans group streptococci have been obtained by gene 
transfer from S. pneumoniae and vice versa [30,35]. 
IN VlTRO SUSCEPTIBILITY 
Minimum inhibitory concentrations 
The increasing prevalence of penicillin-resistant 
S. pneumoniae throughout the world means that there is 
a need for antibiotics with potent activity against these 
organisms. A recent multicenter study, conducted in 
Spain, has compared the activity of third- and fourth- 
generation cephalosporins and the carbapenem, 
iinipenem, against penicillin-susceptible, penicillin- 
intermediate and penicillin-resistant S. pneumorzine 
(Table 2) [36]. The current NCCLS susceptibility 
breakpoints for the cephalosporins, recomniended for 
S. pneumoniae infections are: susceptible, I 0.5 mg/L, 
intermediate resistance, 1 .0 mg/L and resistant, 
2 2 mg/L. Against penicillin-intermediate strains, 
cefpirome, cefotaxime (or ceftriaxone, data not shown) 
were the most active compounds, with MIC,,, values 
of 0.5 mg/L, with cefepime being slightly less active 
(MIC,, value, 1.0 mg/L). 
Against penicillin-resistant strains, cefpirome and 
imipenem were the most active compounds overall, 
with maximum MICs of 1.0 mg/L. Cefepime and 
cefotaxime (or ceftriaxone) were two-fold less active 
and although the difference in MIC values was only 
small, this may be important in the treatment of 
infections, particularly when considering the antibiotic 
levels which are likely to be achieved at the site of 
infection in cases of meningitis. 
Other studies have confirnied a two-fold 
advantage in the in vitro activity of cefpirorne against 
S. pneumoniae compared to cefepime, cefotaxime aiid 
ceftnaxone [31,37,38], and data from South Africa 
(Table 3) also show cefotaxinie and ceftriaxone to be 
two-fold less active than cefpirome, whereas ccfepime 
was four-fold less active than cefpirome against both 
penicillin-intermediate and penicillin-resistant 
pneumococci. The South African strains examined 
were generally less susceptible than that of thc Spanish 
strains, with the MIC,,, values against the penicillin- 
resistant strains being 4 mg/L for penicillin, cefepime 
and cefodizime, and 2 mg/L for cefotaxime aiid 
ceftriaxone. The MIC,, value of cefpirome, however, 
was 1.0 mg/L, the same as for the Spanish strains. 
Ceftazidime was much less active than penicillin 
S 5 2  
Table 2 Susceptibility of strains of S .  pneMmoniae f rom Spain to six p-lactam antibiotics 
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Category Antibiotic MIC (mg/L) 
50% 90% Range 
Penicillin-susceptible 
(MIC 50.06 mg/L) 
n = 100 
Penicillin-intermediate 
(MIC 0.12-1.0 mg/L) 
n = 100 
Pe nicillin-resistant 
(MIC 2 2 mg/L) 
n = 100 
ceftazidiniea 
cefepime 
cefpirome 
cefotaximeb 
irnipenem 
cefiazidime1 
ccfepime 
cefpirome 
cefotaximeb 
imipenem 
ceftazidimea 
cefepime 
ccfpirome 
cefotaximeb 
imipenem 
0.12 
0.015 
0.03 
0.03 
0.008 
4 
0.5 
0.25 
0.25 
0.06 
16 
1 .0 
0.5 
0.5 
0.25 
0.25 
0.03 
0.03 
0.03 
0.008 
8 
1.0 
0.5 
0.5 
0.12 
>32 
1 .0 
1 .0 
1 .0 
0.5 
0.06-0.25 
0.008-0.12 
0.0084l.06 
0.008-0.03 
0.008-0.03 
0.5-16 
0.008-1.0 
0.008-1.0 
0.008-1.0 
0.008-0.25 
16-64 
0.12-2 
0.12-1.0 
0 . 0 6 2  
0.116-1.0 
~ ~ 
dCeftizoxime showed sindar activity to ceftazidime 
bCeftnaxone showed comparable activity to cefotaxime 
Adapted tiom Martinez-Beltrin et a1 (361 
Table 3 Susceptibility of South African strains of S .  ptwumoniae t o  six p-lactam antibiotics 
Antibiotic MIC,, (mg/L)a 
Penicillin-susceptiblc ( n  = 65) Penicillin-intermediate ( n  85) Penicillin-resistant ( n  = 60) 
Penicillin 0.06 1 .o 4 
Cefiazidime 1 .o 16 64 
Cefepime 0.12 2 4 
Cefpirome 0.12 0.5 1 .0 
Cefotaxiiiie 0.06 1.0 2 
Ceftriaxone 0.06 1 .o 2 
Cefodizime 0.12 4 4 
"IC determinations were performed according to NCCLS critcna using the microdilution method. 
or the other cephalosporins tested, with MIC,, values 
for penicillin-intermedate and penicillin-resistant strains 
of 8-16 mg/L and 64 mg/L, respectively (Tables 2 
and 3). The activity of ceftizoxime has been found to 
be similar to ceftazidime and lower than ceftriaxone and 
cefotaxime against penicillin-intermediate and penicillin- 
resistant pneumococci 1311. Although imipenem was 
consistently the most active compound tested, 
meropenem has been shown to be two-fold less active 
than imipenem [31], but more active than cefotaxime 
or ceftriaxone. Amoxicillin has also shown similar 
activity to cefotaxime and ceftriaxone against penicdin- 
intermediate and penicillin-resistant pneumococci 
118,311. 
Penicillin resistance is also increasing among 
viridans streptococci, with up to 49% of strains now 
resistant 119,251. Published reports have confirmed the 
activity of third- and fourth-generation cephalosporins 
against these pathogens [26,39]. In one study, 
comparing the activity of ten cephalosporins against 
a-hemolytic streptococci recovered from blood, 
cefpirome was found to be the most active agent with 
an MIC,o of 1.0 mg/L, followed by cefazolin and 
cefotaxinie, with MIC,, values of 2.0 mg/L [39]. 
Recent data showing the susceptibility of viridans 
streptococci to third- and fourth-generation 
cephalosponns and imipenem are shown in Table 4. 
For intermediate penicillin-resistant strains, cefpirome 
was again two-fold more active than cefotaxime in 
terms of the MIC,, value, and four-fold more active 
than cefepime. The MIC,, values of cefpirome, 
cefocelis, cefepime and cefotaxime against penicillin- 
resistant strains were 8 mg/L and imipenem was two- 
fold more active, with an MIC,, value of 4 mg/L. 
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Table 4 Susceptibility of viridans streptococci from Spain to five p-lactaiii antibiotics 
Category Antibiotic MI<: (tiig/L) 
50% 
- 
90% 
~ 
Range 
Penicillin-susceptible 
(MIC < 0.25 mg/L) 
n = 272 
Penicillin-intermediate 
(MIC 0.25-2.0 mg/L) 
n = 101 
Penicillin-resistant 
(MIC 2 4 mg/L) 
n = 37 
ceftazidiniea 
cefcpime 
cefpiroine 
cefotaxime 
imipenem 
ceftazidiniea 
cefepiiiie 
cefpironie 
ccfotaximr 
imipencm 
ceftazidimr" 
cefepimc 
cefpirome 
cefotaxime 
iinipenem 
1 
0.12 
0.03 
0.06 
0.015 
4 
0.25 
0.12 
0.12 
0.12 
8 
4 
2 
2 
1 .o 
3 - 
0.25 
0.12 
0.25 
0.06 
16 
2 
0.5 
1 .(I 
0.25 
I6  
8 
8 
8 
4 
(J. 1 2-4 
0.01 5-1 .(I 
0.015-0.25 
0.01 .i-0.25 
0.01 5-0.(16 
1 .Oh232 
0.01 5-2 
0.015-1.0 
0.015-1 .0 
0.01 5-0.5 
1.0-32 
1 .0-16 
0.12-8 
0.5-1 6 
0.13-8 
~~ ~ 
Qnly 120 strains were studied (70 sensitive, 25 interniediate-resistant and 25 highly-resistant) 
Adapted from Alcaidc et al. 1251. With permission of Air1 Sac Microbiol J Div. 
Ceftazidime was also shown to have poor activity 
against viridans streptococci, with values of 
16 mg/L for penicillin-intermediate and penicillin- 
resistant strains. This may have clinical implications, as 
penicillin-resistant strains are being implicated more 
frequently in serious infections, particularly those 
caused by viridans streptococci in the: neutropenic 
patient [13,14]. 
Bactericidal activity 
Time-kill studies were performed against penicillin- 
susceptible, penicillin-intermediate arid penicillin- 
resistant pneumococci and viridans streptococci. The 
bactericidal activity of cefpirome was compared with 
those of penicillin and cefotaxirnc a t  2x and 4x the 
MIC values. Cefpirome showed the same degree of 
bactericidal activity as penicillin and cefotaxinie against 
penicillin-susceptible, -intermediate and -resistant strains 
of S .  pneumoniae (Table 5). These results confirm other 
published data [40], where a 3-4 reduction in 
numbers of viable bacteria was achieved within 6 hours, 
for penicillin-intermediate arid penicillin-resistant 
strains of S .  pneumoniae treated with ccfotaxime and 
cefpirome at 2x and 4x the MIC values. The rapid 
Table 5 Bactericidal activities of penicillin, cefotaxime and cefpirome against penicillin-susccptil,le, -intermediate and - 
resistant S .  pneumoniae 
Decrease in numbers of viable bacteria (log cfdrnl) from 0 ha 
Strain Antibiotic MIC 2 x MI<: 4 x MIC 
32928 penicillin 0.03 4.43 2 4.80 
cefotaxiiiie 0.03 4.23 2 4.80 
cefpirome 0.03 4.23 2 4.80 
4.4.3 2 4.80 
4.41 2 4.80 
4.43 2 4.80 
14901 penicillin 0.5 2.74 3.67 
cefotaxime 0.5 2.59 3.60 
cefpirome 0.25 2.59 3.50 
3.1 1 3.73 
2.70 3.67 
2.62 3.53 
1447 1 penicillin 4 2.55 3.52 3.Oi1 3.52 
cefotaxinie 4 2.89 3.65 3.00 3.62 
cefpirome 2 2.96 3.36 3.00 3.52 
aTinie-kill studies were perfomled in cation-supplemented Mueller Hiiiton broth + 2.5% lyzed horse blood. [Baquero, unpublished data]. 
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bactericidal effect may play a role in the therapeutic 
response of pneumococci to these agents. 
In contrast, in the case of the viridans streptococci, 
the bactericidal activity was very low for penicillin, 
cefpirome and cefotaxime against the penicillin- 
intermediate and penicillin-resistant strains, with only 
1-2 logl0 decreases being achieved by 6 hours at 4x 
the MIC values. This suggested that infections caused 
by these organisms may be refractory to monotherapy, 
particularly in the setting of endocarditis. All three 
compounds showed similar rates of bactericidal 
activity, however, the only difference seen was against 
the penicillin-susceptible strain, where the bactericidal 
effect of penicillin was slightly better than for the 
cephalosporins at 2x MIC. 
Antibiotic combinations 
For serious infections involving streptococci, a p-lactam, 
often in combination with another agent such as a 
glycopeptide or an aminoglycoside, may be used for 
empirical therapy. The activity of penicillin and 
cefpirome in combination with other agents was 
measured using chequerboard MIC determinations. 
The results show total and partial (or additive) 
synergistic interactions between penicillin or 
cefpirome and vancomycin, fosfomycin or gentamicin 
against 15 strains of intermediate and high-level 
penicillin-resistant strains of S .  pneumoniue and 
viridans streptococci (Table 6). Synergy was calculated 
using fractional inhibitory concentrations (FICs) [41]. 
In general, against S .  pneumoniae, vancomycin 
demonstrated a lower frequency of total synergistic 
interactions than fosfomycin or gentamicin when 
combined with penicillin, but 80% of the strains 
showed partial synergy. For fosfomycin, combined 
with penicillin or cefpirome, either partial or total 
synergy was seen against all the strains. A similar 
situation was seen for gentamicin in combination with 
penicillin, but, curiously, gentamicin plus cefpirome 
did not show such a high level of synergy as with 
penicillin (Table 6). 
Despite only partial synergy being demonstrated 
between cefpirome and vancomycin in chequerboard 
MIC studies against penicillin-resistant pneumococci, 
time-kill studies against 9 strains of S .  pneumoniae 
(3 penicillin-susceptible, 3 penicillin-intermediate and 
3 penicillin-resistant) demonstrated synergistic 
interactions (synergy was defined as a 2 2 logl0 decrease 
in viable count with the combination compared with the 
more active of each of the two compounds tested alone) 
(Table 7 ) .  The concentrations of cefpirome ( lx  MIC) 
and vancomycin ( 0 . 5 ~  MIC) used showed little or no 
bactericidal activity when tested alone, but showed a 
decrease of at least 3 logl0 in the numbers of viable 
bacteria by 6 hours when tested in combination, for 
all nine strains of S .  pnemmoniue. 
In a further study conducted by Bajakouzian et al. 
[42], cefpirome and cefotaxime demonstrated 
synergistic or additive interactions with vancomycin 
and teicoplanin against penicillin-susceptible, 
-intermediate and -resistant pneumococci, using 
MIC chequerboard titration, with none of the 
combinations being antagonistic. In time-kill studies 
all four combinations demonstrated synergy against 
nine strains. 
The same pattern of synergistic interactions was 
seen with the viridans streptococci (Table 6). 
Cefpirome was slightly less synergistic than penicillin 
with vancomycin, fosfomycin or gentamicin against 
the viridans streptococci; nevertheless, more than 50% 
of the strains showed either total or partial synergy for 
all the combinations tested. 
Overall, these data suggest that there would be an 
advantage, in terms of antibacterial activity, in combining 
Table 6 Strains of S. pneumonine and viridans streptococci (penicillin-intermediate and -resistant) in which FICa indces in 
chequerboard titration indicate drug synergism or additive activity 
% strains 
Penicillin- Penicillin- Penicillin- Cefpirome- Cefpirome- Cefpirome- 
vancomycin fosfornycin gentamicin vancomycin fosfomycin gentamicin 
S .  pneumoniae Synergy 20 60 60 n 45 25 
Additive 80 100 95 95 100 50 
Vindans 
streptococci Synergy 30 60 65 10 40 20 
Additive 70 100 a5 60 100 50 
3The FlCs were calculated as the MICs of both drugs in combinatiodthe MIC for the drug alone, and the FIC index was obtained by adding 
the FIG.  FIC indices were interpreted as synergistic if the values were 5 0.5, partial or additive if the values were > 0.5-1.0, and 
antagonistic if the values were > 1.0. [Baquero, unpublished data]. 
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Table 7 Bactericidal activities of cefpirome and vancomycin, alone and in combination, against nine strains of S. pnecrrnoniae 
Change in loglo bacterial colony count from 0 ha 
Strain 4 h  6 h  
Cefpiromeb Vancomycinc Cefpiromeb + Cefpiromeb Vancomycinc Cefpcromeb + 
vancomycin' vanconiycinc 
S13 - 0.89 + 0.11 
S32 + 0.74 - 0.50 
s40 + 0.66 + 1.53 
I10 + 0.55 + 0.33 
141 - 0.43 + 0.32 
1145 + 0.18 + 0.46 
R11 + 0.27 + 0.82 
R13 + 1.37 + 2.39 
K14 - 0.18 + 0.33 
Mean f SD +0.25 f 0.64 +0.64 3.0.8 
- 3.48 
- 3.73 
- 3.24 
- 4.62 
- 3.62 
- 2.37 
- 2.73 
- 4.29 
- 2.55 
-3.4 f 0.72 
- 0.23 + 0.62 - 4.56 
+ 0.81 + 1.05 - 4.30 
+ 0.79 + 1.61 - 3.70 
+ 1.31 + 2.21 - 5.18 
- 1.76 + 0.40 - 3.98 
+ 0.93 + 1.7'1 - 4.00 
+ 2.15 + 1.92 - 4.57 
+ 2.70 + 2.94 - 4.53 
+ 1.67 + 1.80 -5.00 
+0.82 f 1.12 +1.59 k 0.75 -4.42 f 0.46 
aTime-kill studies were performed in cation-supplemented Mueller Hinton broth + 2.5% lyzed horse blood. 
bCCelpirome was tested at 1 x MIC. 
CVancomycin was tested at 0.25 mg/L (0.5 x MIC: for all strains). 
a p-lactam antibiotic (penicillin or cefpirome) with 
another agent (glycopeptide, fosfomycin or gentamicin) 
when treating some infections caused ]by penicillin- 
resistant streptococci, although this needs to be 
confirmed by in vivo and clinical studies. 
CLINICAL IMPLICATIONS 
Many strains of pneumococci are multidmg-resistant 
and strains with resistance to the third-generation 
cephalosporins are being reported [21,43]. The  
appropriate antibiotic therapy for pneumococcal 
infections due to resistant strains still remains 
controversial. In an attempt to address this problem, 
the relationship between in vitro data and clinical 
outcome must be considered. Selection of antibiotics 
should be made on the basis of the site of infection, 
the need for bactericidal activii;y and the 
pharmacodynamic properties of the conipound [44]. 
Pneumococcal pneumonia 
The results of a 10-year prospective study of 504 
patients with bacteriologically-proven pneumococcal 
pneumonia were reported in 1995 [45]. Of  these, 29% 
were infected with penicillin-resistant strains 
(penicillin MIC values, 0 . 1 2 4  mg/L) and 6% had 
cephalosporin-resistant strains (cefotaxime MIC 
values, 1-4 mg/L). Although differenccs were found 
in the mortality rate in nosocomial pneumonia caused 
by penicillin-resistant (38% mortality) and penicillin- 
susceptible (24% mortality) strains of S .  pneumoniae, 
when the data were adjusted to take into account 
polymicrobial infections and the type of underlying 
illness, there was no difference between the two groups. 
Amongst patients treated with ampicillin or penicillin G, 
the mortality rate was 25% in patients with penicillin- 
resistant strains and 19% in patients with penicillin- 
susceptible strains and, amongst patients treated with 
ceftriaxone or cefotaxime, the mortality rate was 22% 
for penicillin-resistant strains and 25% for penicillin- 
susceptible strains. Furthermore, for patients treated with 
cefotaxime or ceftriaxone, the mortality rate was 22% 
for cephalosporin-resistant S. yneumoniae and 24% for 
cephalosporin-sensitive strains. 
Another study [46], also denionstrated no  
difference in the mortality rate in children with 
pneumococcal bacteremia caused by penicillin- 
resistant strains of pneumococci (1 4%4, compared 
with that seen in children infected with penicillin- 
susceptible strains (11%). More recent data show that 
there was no difference in time to resolution of signs 
and symptoms, and the clinical course was similar, for 
intravenous penicillin or ampicillin therapy of 
penicillin-resistant and penicihn-sensitive pneumococcal 
pneumonia in children [47]. Similar observations were 
seen in patients treated for pneumonia caused by 
strains of pneumococci which were resistant in vitro 
to cefuroxime but responded clinically [48,491. 
These data suggest that penicillin MIC values are 
not the primary determinant predicting the clinical 
outcome of pneumococcal pneumonia, at least up to 
an MIC value of 4 mg/L. In order to examine the 
response of penicillin-susceptible and penicillin- 
resistant pneumococci to treatment with penicillin in 
more detail, Figure 2 shows a peritonitis mouse model 
used to determine the 50% effective dose (EDSO) of 
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Figure 2 Effect of increasing the MIC values of penicillin 
on the 50% effective dose (ED7o), in a S. przeumoniue peritonitis 
inouse model following penicillin treatment. From Knudscn 
et al. [50]. With pemiission of Am Soc Microbiol J Div. 
penicillin against strains of S. yneumoniae with different 
penicillin MIC values [SO]. There was little difference 
in the ED,, of penicillin in mice infected with strains 
with MIC values ranging from 0.016-0.5 rng/L. For 
strains with higher MIC values (> 1 mg/L), however, 
the ED,, increased in a stepwise fashion. This continued 
up to an MIC value of 4 mg/L, following which the 
ED,, levelled out at around 45 mg/kg. This means 
that small differences in MIC could be crucial in 
determining the clinical outcome, particularly in certain 
infections. In pneumonia, the concentrations of 
antibiotic achieved at the site of infection are probably 
high enough to cope with strains with MIC values up 
to 4 mg/L, so no difference in efficacy would be seen 
for strains with MIC values of0.1-4 mg/L [45]. 
For patients in whom suspected pneuniococcal 
pneumonia is caused by highly-resistant strains and, in 
addition, an underlying immunodeficiency, an 
alternative regimen would be to use third- or fourth- 
generation cephalosporins with enhanced activity against 
these strains or a carbapenem [Sl]. The bactericidal 
activity of p-lactams is concentration-independent 
and time above MIC correlates most closely with 
clinical outcome [44]. If the maximum concentrations 
of cefpirome achieved in serum are examined for 
standard dosage; the peak serum concentration after 
an intravenous injection of 2 g is 173 mg/L [52], 
whereas that for a 1 g dose is 81 mg/L. The half-life 
of cefpirome is 2 hours so that, for the 2 g intravenous 
dose, the serum concentration of cefpirome exceeds 
the maximum MIC value observed against penicillin- 
resistant pneumococci (penicillin MIC 4 nig/L; 
cefpirome MIC I mg/L) for the whole 12-hour 
dosing interval. This concentration is exceeded for 
around 10 hours following a 1 g intravenous dose and 
for the whole 12-hour dosing interval following 
adnllnistration of a 3 g intramuscular dose, although the 
serum peak was only 22 mg/L in the latter case [52]. 
The maximum MIC value against penicillin- 
intermediate strains of viridans streptococci is 1 .O mg/L 
and these strains are therefore well covered by 
concentrations of cefjirorne achieved in serum, whereas 
the maximum MIC value against penicillin-resistant 
strains (8 mg/L) is exceeded in serum for 6-8 hours 
following intravenous or intramuscular dosage of 2 g 
cefpirome. This time above MIC of 50-67% of the 
dosing interval may be sufficient for clinical efficacy, 
although this is questionable for neutropenic patients, 
and needs to be investigated using in vivo models or 
clinical studies. It is also important to stress that current 
resistance levels may increase and recommended 
dosage levels and regimens may have to be increased 
likewise. Alternatively, combination therapy could be 
considered. The results of in vitro synergy studies 
suggest that a combination of a p-lactam with an 
aminoglycoside should bc the treatment of choice 
against penicillin-resistant viridans streptococcal 
endocarditis, and this needs to be confirmed clinically. 
Meningitis 
At present, the third-generation cephalosporins, 
cefotaxime and ceftriaxone, are the preferred antibiotics 
for initial empiric therapy for suspected pneumococcal 
meningitis. Most penicillin-resistant strains are 
inhibited by a niaxiniuni MIC of 2 mg/L. Failure of 
cephalosporin treatment is increasingly reported with 
strains having MIC values of 2 2 mg/L and cefotaxime 
or ceftnaxone should not be used alone to treat 
resistant cases [Sl]. For resistant strains, vancomycin or 
rifampicin should be used in addition to the third- 
generation cephalosporin. An alternative could be the 
use of new classes of antibiotic such as the 
carbapenems or the fourth-generation cephalosporins. 
Meropenem has been used to treat a large number of 
children with meningtis, but more data are required 
on the treatment of penicillin-resistant strains [53]. 
Clinical trials are also needed to support the use of the 
fourth-generation cephalosporins in this indication. 
In meningtis, it is the concentration of antibiotic 
in the cerebrospinal fluid (CSF) which is important in 
determining clinical outcome. In an experimental 
pneumococcal meningitis infection in rabbits, the 
fourth-generation cephalosporins, cefpirome and 
cefepime demonstrated good penetration into CSF 
compared to cefotaxime [S4]. Following intravenous 
infusion of cefepime at 25 mg/kg/h and cefpirome at 
10 mg/kg/h, 9.6 and 6.6 mg/L, respectively were 
achieved in the CSF, indicating 16.2% and 19.3% 
penetration. I n  contrast, cefotaxime attained only 
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2.3 mg/L following a 50 mg/kg/h intravenous i h s i o n ,  
indicating 4.3% penetration. In another pneumococcal 
meningitis rabbit model [55], the efficacy of several 
agents and combinations were compared against 
penicillin-sensitive and -resistant strain:;. This study 
confirmed the excellent CSF penetration of cefpirome 
compared to meropenem, rifampicin and vancomycin. 
A f u r t h e r  s tudy  f o u n d  mean  peak  CSF  
concentrations of cefpirome of 4 mg/L, obtained 
4 hours after an intravenous dose of 2 g cefpirome, 
in adult patients with purulent meningitis [56]. A 
more recent study, in which children were administered 
300 mg/kg cefotaxime, showed mean levels of 4-5 mg 
cefotaximdl in CSF, with wide variability, such that 
some patients had levels below 1.0 mg/'L [Friedland, 
Klugman, personal communication]. Preliminary 
studies with cefpirome in children suggest that the 
penetration of cefpirome into CSF is better than that 
of cefotaxime [Friedland, unpublished data]. The 
concentration of cefpirome reported in the CSF of 
adults with purulent meningitis [56] 'exceeded the 
maximum MIC value of cefpironie against penicillin- 
resistant S. pneumoniue and penicilliwintermediate 
viridans streptococci (1.0 mg/L) for the whole 12-hour 
dosing interval. 
Other experimental drugs, such as the new 
quinolones (sparfloxacin, clinafloxacin, grepafloxacin, 
levofloxacin, trovafloxacin), oral arid parenteral 
streptograminins (quinupristin/dalfopristin) and the 
oxazolidinones (U-100572, U-100766), have shown 
promising activity in vitro against penicillin-resistant 
pneumococci. The therapeutic usefulness of these 
agents must await toxicological, pharmaLcokinetic and 
clinical studies [19,43]. 
SUMMARY 
The incidence of penicillin resistance amongst 
S. przeumoniae is increasing at such a rapid rate that we 
are currently facing a pandemic situation. Many 
penicillin-resistant pneumococci are multiresistant, 
precluding the use of alternative agents, such as the 
macrolides, tetracyclines and chloramphenicol [6-10]. 
The treatment of choice for most ~pneumococcal 
infections remains a p-lactam antibiotic. Fourth- 
generation cephalosporins, such as cefpirome, have 
shown potent activity against penkillin-resistant 
pneumococci, being more active than cefotaxime and 
ceftriaxone, the current p-lactam agent; of choice. 
The antibiotic management of meningitis, in 
particular, has been complicated by the emergence of 
penicillin- and cephalosporin-resistant- strains. The 
third-generation cephalosporins (ce fotaxime and 
ceftriaxone) are now the empirical drugs of choice for 
the management of pneuniococcal meningitis. For 
resistant strains, a glycopeptide or rifanipicin should be 
added to the regimen. An alternative to this could be 
the use of new classes such as the carbapenerns or 
fourth-generation cephalosporins, although more 
clinical data are needed. 
Viridans streptococci have also acquired penicillin 
resistance [15-171, via the same mechanism as 
S. pneumoniae [30] and, although there are less 
epidemiological data for this group of organisms, they 
are increasingly being implicated in serious infections, 
such as meningitis and bacteremia, particularly in 
neutropenic patients. Penicillin-resistant viridans 
streptococci are potentially a much greater problem as 
they are less susceptible, and show tolerance to all the 
p-lactam antibiotics tested. 
The current MIC breakpoints for susceptibility to 
p-lactam antibiotics may need to be modified, to 
reflect recent clinical data. For instance, in pneumonia 
or bacteremia, streptococci up to a certain level of 
penicillin resistance will respond to conventional 
p-lactain therapy, but in the case of infections in 
closed compartments, such as meningitis or otitis media, 
a lower breakpoint may be required. 
DISCUSSION 
Prof. M. Glauser: Regarding the map which 
illustrates the world-wide distribution of intermediate 
and penicillin-resistant pneumococci, are data available 
regarding the corresponding figures for high level 
penicillin-resistant pneumococc-i, as these organisms 
are the most important in the clinical situation? 
Prof. F .  Baquero: The number of countries 
represented will be extremely low, as there are very 
few data available concerning high-level penicillin 
resistance, and this will differ from country to country. 
In most southern European countries, such as Spain, 
Portugal or France, the rate of  high-level resistance 
among the total number of strains is approximately 
33%. In some other countries wch as Germany, the 
rate of penicillin-resistant pneumococci is 1 O N ,  
although these are mainly intermediately penicillin- 
resistant strains. 
Prof. K. Klugman: In countries with a low rate of 
penicillin resistance, most of the strains will be 
intermediately penicillin-resistant. South Africa is an 
exception, as a problem with penicillin resistance 
(intermediate and high-level) has been in existence for 
many years; there is also a wide diversity of clones. 
However, the actual incidence of high-level penicillin 
resistance is quite low in South Africa. Unfortunately, 
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in most of the parts of the world where resistance is 
rapidly developing, such as South America, Australia, 
Western Europe and the USA, approximately a third 
of strains are highly penicillin-resistant. 
Prof. M. Glauser: Are there more data regarding the 
incidence of penicillin resistance among viridans 
group streptococci? 
Prof. F. Baquero: There are currently only limited 
data available and for countries where data has been 
published, the rate of penicillin resistance is high. For 
instance, in Spain the rate of penicillin resistance is 
nearly 30% and in the USA and South Africa the rate 
is nearly 40%. 
It would be valuable to obtain data for France and 
to compare the rates of penicillin resistance among 
pneumococci and viridans group streptococci, as there 
is some evidence that viridans streptococci acquired 
penicillin resistance before the pneumococci. 
Prof. W. Wilson: Dr G. Doern from the NCCLS 
has proposed a lower breakpoint for penicillin against 
viridans group streptococci than for the cephalosporins. 
This means that the penicillin-intermediate range of 
0.25-2 mg/L is quite high for penicillin susceptibility 
for viridans streptococci. 
Prof. F. Baquero: In terms of PBP alterations and 
the MIC distribution profile, the current susceptibility 
breakpoints are still applicable but they may not be 
clinically relevant. 
Prof. K. Klugman: In our experience ceftriaxone is 
still effective, at least in combination, in treating 
endocarditis caused by viridans streptococci. However, 
it is not known to what extent highly penicillin- 
resistant strains are involved. 
Prof. P. Francioli: One hundred cases of endocarditis 
have been treated using a 2 g dose of ceftriaxone, 
although only a very few patients had strains with 
MICs > 0.25 mg/L. An alternative regimen would 
be combining ceftriaxone with an aminoglycoside, 
particularly for strains with MICs > 0.5 mg/L. 
Prof. W. Wilson: Over a 35 year period at the Mayo 
Clinic, approximately a third of patients with 
endocarditis had tolerant viridans streptococci and 4% 
had intermediately penicillin-resistant viridans 
streptococci (i.e. MIC > 0.5 mg/L). All patients were 
treated successfully with combination therapy of 
penicillin plus an aminoglycoside, even patients with 
susceptible organisms. In animal infection models, 
data have shown that strains with increased penicillin 
resistance did not respond as well to monotherapy 
compared with the fully susceptible strains. The 
American HEART statement published in JAMA 
about eight months ago suggested that combination 
therapy for the first two weeks of a four week regimen 
and Infection, Volume 3 Supplement 1, Apr i l  1997 
was recommended for strains with MICs, 0.1-0.5 mg/L. 
For strains with MICs > 0.5mg/L it was suggested 
that therapy should be similar to that for enterococcal 
endocarditis. 
Prof. K. Klugman: In meningtis, there is wide variation 
in the CSF penetration of cefotaxime. The penetration 
is insufficient to cover strains with MICs of 2 2 mg/L, even 
when using a higher dose of cefotaxime (300 mg/kg/day). 
In these cases combination therapy with vancomycin is 
recommended. Clinical studies with compounds such as 
cefpirome as monotherapy warrant further investigation. 
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